TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

Neurogene Inc.
Merger with Neoleukin Therapeutics (Nasdaq:NLTX)

The mission of Neurogene Inc. ("Neurogene" or the "company") is to turn devastating neurological diseases into treatable conditions to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and by designing products to maximize potency and purity for an optimized efficacy and safety profile. The company’s novel and proprietary EXACT gene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy.

Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins.

More Like This

May 2020
$2 Billion

10-Year Strategic Collaboration with Arcus Biosciences, Inc.

Financial Advisor

View Details >
Oct 2018
Ideal Option

Strategic Investment by Varsity Healthcare Partners

Financial Advisor

View Details >
May 2018
Community Medical Services

Recapitalisation by Clearview Capital, LLC

Financial Advisor

View Details >